Cargando…

Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports

INTRODUCTION: Imatinib mesylate (Glivec(®)/Gleevec(®)) is the standard first-line therapy for the treatment of chronic myeloid leukemia due to its high hematologic, cytogenetic, and molecular response rates and favorable long-term safety profile. A copy version of imatinib is currently available in...

Descripción completa

Detalles Bibliográficos
Autores principales: Asfour, Inas A, Elshazly, Shereen A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803998/
https://www.ncbi.nlm.nih.gov/pubmed/20062598
http://dx.doi.org/10.1186/1757-1626-2-9342
_version_ 1782176121648840704
author Asfour, Inas A
Elshazly, Shereen A
author_facet Asfour, Inas A
Elshazly, Shereen A
author_sort Asfour, Inas A
collection PubMed
description INTRODUCTION: Imatinib mesylate (Glivec(®)/Gleevec(®)) is the standard first-line therapy for the treatment of chronic myeloid leukemia due to its high hematologic, cytogenetic, and molecular response rates and favorable long-term safety profile. A copy version of imatinib is currently available in several countries. We report on two cases of CML who were originally treated with Glivec in Egypt and subsequently switched to the copy drug CASE PRESENTATION: Case one was a 35-year old female with chronic myeloid leukemia in blast crisis who began treatment with combination chemotherapy and Glivec. The patient achieved and maintained a complete hematologic response and continued on Glivec 400 mg/day. In March 2007, she was switched to the copy drug In September 2007, the patient presented in hematologic relapse. At this time, treatment with chemotherapy in combination with Glivec 400 mg/day was resumed. The patient quickly achieved, and maintained, complete hematologic response on Glivec 400 mg/day. The second patient was a 64-year old male with chronic myeloid leukemia in blast crisis who began treatment with truncated chemotherapy in combination with Glivec 400 mg/day. After 6 months, the patient achieved a partial hematologic response and continued on alternating cycles of chemotherapy with continuous administration of Glivec 400 mg/day. The patient received Glivec from January 2006 to February 2007, after which time he was switched to the copy drug. In November 2007, he presented with upper gastrointestinal bleeding and multiple gastric erosions and died the same day. CONCLUSION: The safety and efficacy of the copy drug has not been established in randomized clinical trials. It is unknown whether patients, who respond to Glivec and then switch to copy versions of imatinib, will tolerate the copy drug and maintain their response.
format Text
id pubmed-2803998
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28039982010-01-10 Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports Asfour, Inas A Elshazly, Shereen A Cases J Case Report INTRODUCTION: Imatinib mesylate (Glivec(®)/Gleevec(®)) is the standard first-line therapy for the treatment of chronic myeloid leukemia due to its high hematologic, cytogenetic, and molecular response rates and favorable long-term safety profile. A copy version of imatinib is currently available in several countries. We report on two cases of CML who were originally treated with Glivec in Egypt and subsequently switched to the copy drug CASE PRESENTATION: Case one was a 35-year old female with chronic myeloid leukemia in blast crisis who began treatment with combination chemotherapy and Glivec. The patient achieved and maintained a complete hematologic response and continued on Glivec 400 mg/day. In March 2007, she was switched to the copy drug In September 2007, the patient presented in hematologic relapse. At this time, treatment with chemotherapy in combination with Glivec 400 mg/day was resumed. The patient quickly achieved, and maintained, complete hematologic response on Glivec 400 mg/day. The second patient was a 64-year old male with chronic myeloid leukemia in blast crisis who began treatment with truncated chemotherapy in combination with Glivec 400 mg/day. After 6 months, the patient achieved a partial hematologic response and continued on alternating cycles of chemotherapy with continuous administration of Glivec 400 mg/day. The patient received Glivec from January 2006 to February 2007, after which time he was switched to the copy drug. In November 2007, he presented with upper gastrointestinal bleeding and multiple gastric erosions and died the same day. CONCLUSION: The safety and efficacy of the copy drug has not been established in randomized clinical trials. It is unknown whether patients, who respond to Glivec and then switch to copy versions of imatinib, will tolerate the copy drug and maintain their response. BioMed Central 2009-12-17 /pmc/articles/PMC2803998/ /pubmed/20062598 http://dx.doi.org/10.1186/1757-1626-2-9342 Text en Copyright ©2009 Asfour and Elshazly; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Asfour, Inas A
Elshazly, Shereen A
Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
title Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
title_full Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
title_fullStr Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
title_full_unstemmed Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
title_short Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
title_sort changing therapy from glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803998/
https://www.ncbi.nlm.nih.gov/pubmed/20062598
http://dx.doi.org/10.1186/1757-1626-2-9342
work_keys_str_mv AT asfourinasa changingtherapyfromglivectoacopyimatinibresultsinaworseningofchronicmyeloidleukemiadiseasestatustwocasereports
AT elshazlyshereena changingtherapyfromglivectoacopyimatinibresultsinaworseningofchronicmyeloidleukemiadiseasestatustwocasereports